drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01142 | DB01392 | 1,264 | 425 | [
"DDInter593",
"DDInter1954"
] | Doxepin | Yohimbine | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac. | Moderate | 1 | [
[
[
1264,
24,
425
]
],
[
[
1264,
63,
1340
],
[
1340,
1,
425
]
],
[
[
1264,
63,
1245
],
[
1245,
40,
425
]
],
[
[
1264,
6,
5700
],
[
5700,
... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Yohimbine"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deserpidine"
],
[
"D... | Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Deserpidine and Deserpidine (Compound) resembles Yohimbine (Compound)
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Reserpine and Reserpine (Compound) resembles Yohimbine (Compound)
Doxepin ... |
DB00939 | DB08901 | 1,338 | 1,468 | [
"DDInter1135",
"DDInter1492"
] | Meclofenamic acid | Ponatinib | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Major | 2 | [
[
[
1338,
25,
1468
]
],
[
[
1338,
18,
6212
],
[
6212,
57,
1468
]
],
[
[
1338,
21,
28852
],
[
28852,
60,
1468
]
],
[
[
1338,
62,
1194
],
[
... | [
[
[
"Meclofenamic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Meclofenamic acid",
"{u} (Compound) downregulates {v} (Gene)",
"CSRP1"
],
[
"CSRP1",
"{u} (Gene) is downregulated by {v} ... | Meclofenamic acid (Compound) downregulates CSRP1 (Gene) and CSRP1 (Gene) is downregulated by Ponatinib (Compound)
Meclofenamic acid (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Ponatinib (Compound)
Meclofenamic acid may cause a minor interaction that can limit clinical effects wh... |
DB00877 | DB13886 | 629 | 125 | [
"DDInter1678",
"DDInter870"
] | Sirolimus | Human cytomegalovirus immune globulin | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Cytomegalovirus immunoglobulin is obtained from pooled adult human plasma selected for high titers of antibody for cytomegalovirus (CMV). It contains purified immunoglobulin G (IgG) antibodies targeting cytomegalovirus (CMV)[FDA label]. Cytomegalovirus, a member of the herpes virus family, is ubiquitous the human popul... | Major | 2 | [
[
[
629,
25,
125
]
],
[
[
629,
64,
1512
],
[
1512,
25,
125
]
],
[
[
629,
25,
712
],
[
712,
25,
125
]
],
[
[
629,
64,
1512
],
[
1512,
... | [
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Human cytomegalovirus immune globulin"
]
],
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diclofenac"
],
[
"... | Sirolimus may lead to a major life threatening interaction when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Human cytomegalovirus immune globulin
Sirolimus may lead to a major life threatening interaction when taken with Olsalazine and Olsalazine may lead to a m... |
DB09143 | DB12457 | 313 | 1,180 | [
"DDInter1701",
"DDInter1598"
] | Sonidegib | Rimegepant | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several p... | Moderate | 1 | [
[
[
313,
24,
1180
]
],
[
[
313,
24,
1619
],
[
1619,
24,
1180
]
],
[
[
313,
64,
1419
],
[
1419,
24,
1180
]
],
[
[
313,
25,
351
],
[
351,
... | [
[
[
"Sonidegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rimegepant"
]
],
[
[
"Sonidegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
... | Sonidegib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Sonidegib may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a modera... |
DB01165 | DB01261 | 1,539 | 170 | [
"DDInter1325",
"DDInter1679"
] | Ofloxacin | Sitagliptin | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Moderate | 1 | [
[
[
1539,
24,
170
]
],
[
[
1539,
7,
5774
],
[
5774,
46,
170
]
],
[
[
1539,
18,
9229
],
[
9229,
57,
170
]
],
[
[
1539,
21,
28850
],
[
28850... | [
[
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Ofloxacin",
"{u} (Compound) upregulates {v} (Gene)",
"SELL"
],
[
"SELL",
"{u} (Gene) is upregulated by {v} (Comp... | Ofloxacin (Compound) upregulates SELL (Gene) and SELL (Gene) is upregulated by Sitagliptin (Compound)
Ofloxacin (Compound) downregulates PAPD7 (Gene) and PAPD7 (Gene) is downregulated by Sitagliptin (Compound)
Ofloxacin (Compound) causes Back pain (Side Effect) and Back pain (Side Effect) is caused by Sitagliptin (Comp... |
DB00377 | DB06176 | 1,494 | 1,342 | [
"DDInter1382",
"DDInter1616"
] | Palonosetron | Romidepsin | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
1494,
24,
1342
]
],
[
[
1494,
23,
1247
],
[
1247,
23,
1342
]
],
[
[
1494,
24,
956
],
[
956,
24,
1342
]
],
[
[
1494,
24,
1616
],
[
1616... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Palonosetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Palonosetron may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Norfloxac... |
DB00421 | DB00595 | 443 | 1,545 | [
"DDInter1707",
"DDInter1374"
] | Spironolactone | Oxytetracycline | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were disco... | A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions. | Minor | 0 | [
[
[
443,
23,
1545
]
],
[
[
443,
62,
964
],
[
964,
1,
1545
]
],
[
[
443,
23,
1620
],
[
1620,
1,
1545
]
],
[
[
443,
24,
603
],
[
603,
... | [
[
[
"Spironolactone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Oxytetracycline"
]
],
[
[
"Spironolactone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doxycycline"
]... | Spironolactone may cause a minor interaction that can limit clinical effects when taken with Doxycycline and Doxycycline (Compound) resembles Oxytetracycline (Compound)
Spironolactone may cause a minor interaction that can limit clinical effects when taken with Tetracycline and Tetracycline (Compound) resembles Oxytetr... |
DB00069 | DB00330 | 367 | 238 | [
"DDInter946",
"DDInter689"
] | Interferon alfacon-1 | Ethambutol | Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional am... | Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and [pyrazinamide] in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of _Mycob... | Moderate | 1 | [
[
[
367,
24,
238
]
],
[
[
367,
63,
1057
],
[
1057,
24,
238
]
],
[
[
367,
24,
458
],
[
458,
63,
238
]
],
[
[
367,
24,
10
],
[
10,
24,... | [
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethambutol"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanerc... | Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Ethambutol
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with T... |
DB01069 | DB01114 | 401 | 272 | [
"DDInter1533",
"DDInter362"
] | Promethazine | Chlorpheniramine | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
401,
24,
272
]
],
[
[
401,
35,
358
],
[
358,
63,
272
]
],
[
[
401,
24,
1237
],
[
1237,
63,
272
]
],
[
[
401,
1,
11275
],
[
11275,
... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Promethazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases wh... | Promethazine (Compound) resembles Orphenadrine (Compound) and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Promethazine may cause a moderate inte... |
DB00880 | DB09082 | 359 | 659 | [
"DDInter360",
"DDInter1934"
] | Chlorothiazide | Vilanterol | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
359,
24,
659
]
],
[
[
359,
24,
1220
],
[
1220,
23,
659
]
],
[
[
359,
63,
891
],
[
891,
23,
659
]
],
[
[
359,
24,
1296
],
[
1296,
... | [
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
... | Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Prednisol... |
DB01149 | DB05812 | 851 | 1,374 | [
"DDInter1274",
"DDInter8"
] | Nefazodone | Abiraterone | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Minor | 0 | [
[
[
851,
23,
1374
]
],
[
[
851,
6,
12523
],
[
12523,
45,
1374
]
],
[
[
851,
21,
28809
],
[
28809,
60,
1374
]
],
[
[
851,
23,
466
],
[
466,... | [
[
[
"Nefazodone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Abiraterone"
]
],
[
[
"Nefazodone",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
... | Nefazodone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Abiraterone (Compound)
Nefazodone (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Abiraterone (Compound)
Nefazodone may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Da... |
DB00959 | DB14783 | 1,486 | 287 | [
"DDInter1191",
"DDInter574"
] | Methylprednisolone | Diroximel fumarate | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
1486,
24,
287
]
],
[
[
1486,
63,
1101
],
[
1101,
24,
287
]
],
[
[
1486,
25,
384
],
[
384,
24,
287
]
],
[
[
1486,
40,
1220
],
[
1220,
... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bex... | Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Methylprednisolone may lead to a major life threatening interaction when taken with Idelalisib a... |
DB00342 | DB01041 | 1,181 | 770 | [
"DDInter1770",
"DDInter1789"
] | Terfenadine | Thalidomide | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
1181,
24,
770
]
],
[
[
1181,
25,
609
],
[
609,
63,
770
]
],
[
[
1181,
25,
684
],
[
684,
24,
770
]
],
[
[
1181,
24,
789
],
[
789,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Cla... | Terfenadine may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Terfenadine may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine may cause ... |
DB01254 | DB08904 | 1,213 | 375 | [
"DDInter484",
"DDInter342"
] | Dasatinib | Certolizumab pegol | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Major | 2 | [
[
[
1213,
25,
375
]
],
[
[
1213,
25,
1047
],
[
1047,
24,
375
]
],
[
[
1213,
64,
704
],
[
704,
24,
375
]
],
[
[
1213,
24,
200
],
[
200,
... | [
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab emtansine"
],
[
"Trastuzu... | Dasatinib may lead to a major life threatening interaction when taken with Trastuzumab emtansine and Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Dasatinib may lead to a major life threatening interaction when taken with Fentanyl and Fentanyl m... |
DB09330 | DB12674 | 985 | 975 | [
"DDInter1352",
"DDInter1105"
] | Osimertinib | Lurbinectedin | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent fou... | Moderate | 1 | [
[
[
985,
24,
975
]
],
[
[
985,
24,
159
],
[
159,
63,
975
]
],
[
[
985,
63,
98
],
[
98,
24,
975
]
],
[
[
985,
64,
918
],
[
918,
24,
... | [
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
... | Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem a... |
DB00046 | DB14509 | 1,179 | 1,399 | [
"DDInter940",
"DDInter1081"
] | Insulin lispro | Lithium carbonate | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
1179,
24,
1399
]
],
[
[
1179,
24,
964
],
[
964,
23,
1399
]
],
[
[
1179,
24,
1385
],
[
1385,
24,
1399
]
],
[
[
1179,
23,
274
],
[
274,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxycycline"... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Semagl... |
DB00862 | DB12332 | 1,005 | 1,619 | [
"DDInter1918",
"DDInter1626"
] | Vardenafil | Rucaparib | Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, ... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1005,
24,
1619
]
],
[
[
1005,
24,
112
],
[
112,
23,
1619
]
],
[
[
1005,
24,
1662
],
[
1662,
24,
1619
]
],
[
[
1005,
63,
1419
],
[
1419... | [
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
... | Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid ... |
DB00095 | DB05015 | 66 | 1,077 | [
"DDInter623",
"DDInter174"
] | Efalizumab | Belinostat | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Moderate | 1 | [
[
[
66,
24,
1077
]
],
[
[
66,
24,
482
],
[
482,
24,
1077
]
],
[
[
66,
24,
1136
],
[
1136,
63,
1077
]
],
[
[
66,
63,
58
],
[
58,
24,
... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belinostat"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Belinostat
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosum... |
DB00668 | DB01142 | 874 | 1,264 | [
"DDInter652",
"DDInter593"
] | Epinephrine | Doxepin | Epinephrine, also known as _adrenaline_, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersensitivity reactions, epinephrine in the auto-injector form (EpiPen) has been avail... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Major | 2 | [
[
[
874,
25,
1264
]
],
[
[
874,
63,
508
],
[
508,
24,
1264
]
],
[
[
874,
24,
401
],
[
401,
24,
1264
]
],
[
[
874,
6,
5299
],
[
5299,
... | [
[
[
"Epinephrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
]
],
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"Promazine",
... | Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Prometh... |
DB00701 | DB06589 | 1,091 | 1,250 | [
"DDInter90",
"DDInter1400"
] | Amprenavir | Pazopanib | Amprenavir is a protease inhibitor used to treat HIV infection. | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Major | 2 | [
[
[
1091,
25,
1250
]
],
[
[
1091,
6,
3486
],
[
3486,
45,
1250
]
],
[
[
1091,
54,
19146
],
[
19146,
15,
1250
]
],
[
[
1091,
21,
29203
],
[
... | [
[
[
"Amprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
]
],
[
[
"Amprenavir",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Pazopani... | Amprenavir (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Pazopanib (Compound)
Amprenavir (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Pazopanib (Compound)
Amprenavir (Compound) causes Aspartate aminotransf... |
DB00286 | DB11827 | 380 | 433 | [
"DDInter439",
"DDInter669"
] | Conjugated estrogens | Ertugliflozin | The conjugated estrogens are noncrystalline mixtures of purified female sex hormones obtained either by its isolation from the urine of pregnant mares or by synthetic generation from vegetal material. Both of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble.... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
380,
24,
433
]
],
[
[
380,
24,
959
],
[
959,
24,
433
]
],
[
[
380,
40,
1438
],
[
1438,
24,
433
]
],
[
[
380,
1,
35
],
[
35,
24,
... | [
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glip... | Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Conjugated estrogens (Compound) resembles Estradiol (Compound) and Estradiol may cause a moderate int... |
DB08896 | DB08930 | 292 | 1,459 | [
"DDInter1576",
"DDInter582"
] | Regorafenib | Dolutegravir | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Dolutegravir is an HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity. Dolutegravir was developed by ViiV Healthcare and ... | Minor | 0 | [
[
[
292,
23,
1459
]
],
[
[
292,
6,
15705
],
[
15705,
45,
1459
]
],
[
[
292,
21,
28722
],
[
28722,
60,
1459
]
],
[
[
292,
63,
1220
],
[
122... | [
[
[
"Regorafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dolutegravir"
]
],
[
[
"Regorafenib",
"{u} (Compound) binds {v} (Gene)",
"UGT1A1"
],
[
"UGT1A1",
"{u} (Gene) is bound by {v} (Compound)... | Regorafenib (Compound) binds UGT1A1 (Gene) and UGT1A1 (Gene) is bound by Dolutegravir (Compound)
Regorafenib (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Dolutegravir (Compound)
Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and ... |
DB00414 | DB06710 | 590 | 1,546 | [
"DDInter16",
"DDInter1193"
] | Acetohexamide | Methyltestosterone | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | A synthetic anabolic steroid used for treating men with testosterone deficiency or similar androgen replacement therapies. Also, has antineoplastic properties and so has been used secondarily in women with advanced breast cancer. Methyltestosterone is a schedule III drug in the US. | Moderate | 1 | [
[
[
590,
24,
1546
]
],
[
[
590,
24,
155
],
[
155,
1,
1546
]
],
[
[
590,
24,
984
],
[
984,
40,
1546
]
],
[
[
590,
63,
989
],
[
989,
1... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyltestosterone"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxymestero... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Fluoxymesterone and Fluoxymesterone (Compound) resembles Methyltestosterone (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Danazol and Danazol (Compound) resembles Meth... |
DB00059 | DB01230 | 1,560 | 795 | [
"DDInter1404",
"DDInter1416"
] | Pegaspargase | Pemoline | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | In 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons. | Moderate | 1 | [
[
[
1560,
24,
795
]
],
[
[
1560,
24,
1613
],
[
1613,
63,
795
]
],
[
[
1560,
24,
267
],
[
267,
24,
795
]
],
[
[
1560,
25,
1510
],
[
1510,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pemoline"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Pemoline
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB01159 | DB06176 | 419 | 1,342 | [
"DDInter854",
"DDInter1616"
] | Halothane | Romidepsin | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required... | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
419,
24,
1342
]
],
[
[
419,
62,
112
],
[
112,
23,
1342
]
],
[
[
419,
63,
485
],
[
485,
24,
1342
]
],
[
[
419,
24,
1616
],
[
1616,
... | [
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Halothane",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Halothane may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Penta... |
DB00353 | DB00357 | 588 | 1,051 | [
"DDInter1187",
"DDInter71"
] | Methylergometrine | Aminoglutethimide | A homolog of ergonovine containing one more CH2 group. (Merck Index, 11th ed) | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Moderate | 1 | [
[
[
588,
24,
1051
]
],
[
[
588,
6,
8374
],
[
8374,
45,
1051
]
],
[
[
588,
21,
28921
],
[
28921,
60,
1051
]
],
[
[
588,
63,
1101
],
[
1101,... | [
[
[
"Methylergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
]
],
[
[
"Methylergometrine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is boun... | Methylergometrine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Aminoglutethimide (Compound)
Methylergometrine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Aminoglutethimide (Compound)
Methylergometrine may cause a moderate interaction that could exacerbate diseases ... |
DB00539 | DB06595 | 11 | 1,491 | [
"DDInter1837",
"DDInter1214"
] | Toremifene | Midostaurin | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Major | 2 | [
[
[
11,
25,
1491
]
],
[
[
11,
23,
112
],
[
112,
23,
1491
]
],
[
[
11,
36,
888
],
[
888,
24,
1491
]
],
[
[
11,
24,
1017
],
[
1017,
63... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
]
],
[
[
"Toremifene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Toremifene may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Toremifene (Compound) resembles Tamoxifen (Compound) and Toremifene may lead to a major life threatening inte... |
DB08815 | DB09280 | 154 | 1,604 | [
"DDInter1104",
"DDInter1101"
] | Lurasidone | Lumacaftor | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Major | 2 | [
[
[
154,
25,
1604
]
],
[
[
154,
63,
473
],
[
473,
24,
1604
]
],
[
[
154,
64,
593
],
[
593,
24,
1604
]
],
[
[
154,
24,
1501
],
[
1501,
... | [
[
[
"Lurasidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
]
],
[
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglini... | Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Lurasidone may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause ... |
DB00757 | DB01246 | 1,166 | 820 | [
"DDInter581",
"DDInter45"
] | Dolasetron | Alimemazine | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | A phenothiazine derivative that is used as an antipruritic. | Major | 2 | [
[
[
1166,
25,
820
]
],
[
[
1166,
25,
401
],
[
401,
24,
820
]
],
[
[
1166,
64,
675
],
[
675,
25,
820
]
],
[
[
1166,
64,
508
],
[
508,
... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alimemazine"
]
],
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"... | Dolasetron may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Dolasetron may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may ... |
DB11793 | DB15762 | 738 | 725 | [
"DDInter1297",
"DDInter1644"
] | Niraparib | Satralizumab | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to [tocilizumab], which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare au... | Moderate | 1 | [
[
[
738,
24,
725
]
],
[
[
738,
63,
1362
],
[
1362,
24,
725
]
],
[
[
738,
24,
270
],
[
270,
24,
725
]
],
[
[
738,
64,
1066
],
[
1066,
... | [
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Satralizumab"
]
],
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
... | Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizum... |
DB01406 | DB12267 | 984 | 1,476 | [
"DDInter472",
"DDInter233"
] | Danazol | Brigatinib | A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
984,
24,
1476
]
],
[
[
984,
25,
1135
],
[
1135,
23,
1476
]
],
[
[
984,
63,
629
],
[
629,
24,
1476
]
],
[
[
984,
24,
951
],
[
951,
... | [
[
[
"Danazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Danazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
... | Danazol may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Danazol may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate i... |
DB00321 | DB01128 | 21 | 918 | [
"DDInter78",
"DDInter204"
] | Amitriptyline | Bicalutamide | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Moderate | 1 | [
[
[
21,
24,
918
]
],
[
[
21,
24,
129
],
[
129,
40,
918
]
],
[
[
21,
6,
8374
],
[
8374,
45,
918
]
],
[
[
21,
21,
28642
],
[
28642,
60... | [
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]... | Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide (Compound) resembles Bicalutamide (Compound)
Amitriptyline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bicalutamide (Compound)
Amitriptyline (Compound) causes Shock (Side Effect) ... |
DB00361 | DB10316 | 134 | 334 | [
"DDInter1939",
"DDInter1248"
] | Vinorelbine | Mumps virus strain B level jeryl lynn live antigen | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Major | 2 | [
[
[
134,
25,
334
]
],
[
[
134,
64,
1057
],
[
1057,
25,
334
]
],
[
[
134,
24,
328
],
[
328,
25,
334
]
],
[
[
134,
25,
908
],
[
908,
2... | [
[
[
"Vinorelbine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Vinorelbine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
... | Vinorelbine may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Mercaptop... |
DB06717 | DB11581 | 875 | 1,456 | [
"DDInter778",
"DDInter1926"
] | Fosaprepitant | Venetoclax | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Major | 2 | [
[
[
875,
25,
1456
]
],
[
[
875,
25,
1135
],
[
1135,
23,
1456
]
],
[
[
875,
25,
1476
],
[
1476,
63,
1456
]
],
[
[
875,
63,
86
],
[
86,
... | [
[
[
"Fosaprepitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
],
[
[
"Fosaprepitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{... | Fosaprepitant may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Venetoclax
Fosaprepitant may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate in... |
DB00501 | DB01035 | 752 | 1,401 | [
"DDInter380",
"DDInter1524"
] | Cimetidine | Procainamide | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | A derivative of procaine with less CNS action. | Moderate | 1 | [
[
[
752,
24,
1401
]
],
[
[
752,
6,
12523
],
[
12523,
45,
1401
]
],
[
[
752,
21,
28658
],
[
28658,
60,
1401
]
],
[
[
752,
24,
2
],
[
2,
... | [
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procainamide"
]
],
[
[
"Cimetidine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)... | Cimetidine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Procainamide (Compound)
Cimetidine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Procainamide (Compound)
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Alosetron and Alo... |
DB05679 | DB11834 | 1,683 | 1,303 | [
"DDInter1907",
"DDInter849"
] | Ustekinumab | Guselkumab | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstra... | Moderate | 1 | [
[
[
1683,
24,
1303
]
],
[
[
1683,
23,
1193
],
[
1193,
23,
1303
]
],
[
[
1683,
62,
1461
],
[
1461,
23,
1303
]
],
[
[
1683,
24,
792
],
[
792... | [
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
]
],
[
[
"Ustekinumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
... | Ustekinumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Guselkumab
Ustekinumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vit... |
DB01394 | DB09291 | 1,554 | 741 | [
"DDInter431",
"DDInter1615"
] | Colchicine | Rolapitant | Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has ... | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Major | 2 | [
[
[
1554,
25,
741
]
],
[
[
1554,
24,
159
],
[
159,
63,
741
]
],
[
[
1554,
63,
973
],
[
973,
24,
741
]
],
[
[
1554,
24,
578
],
[
578,
... | [
[
[
"Colchicine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rolapitant"
]
],
[
[
"Colchicine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotre... | Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and ... |
DB00104 | DB04861 | 966 | 1,592 | [
"DDInter1323",
"DDInter1271"
] | Octreotide | Nebivolol | Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may... | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Moderate | 1 | [
[
[
966,
24,
1592
]
],
[
[
966,
21,
28762
],
[
28762,
60,
1592
]
],
[
[
966,
24,
1450
],
[
1450,
63,
1592
]
],
[
[
966,
63,
1685
],
[
1685... | [
[
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nebivolol"
]
],
[
[
"Octreotide",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused ... | Octreotide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Nebivolol (Compound)
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nebi... |
DB01265 | DB08871 | 1,477 | 36 | [
"DDInter1757",
"DDInter666"
] | Telbivudine | Eribulin | Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects. | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
1477,
24,
36
]
],
[
[
1477,
63,
1488
],
[
1488,
24,
36
]
],
[
[
1477,
40,
231
],
[
231,
24,
36
]
],
[
[
1477,
64,
268
],
[
268,
... | [
[
[
"Telbivudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Telbivudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
],
[
... | Telbivudine may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Telbivudine (Compound) resembles Stavudine (Compound) and Stavudine may cause a moderate interaction that could... |
DB00029 | DB00374 | 25 | 1,061 | [
"DDInter99",
"DDInter1852"
] | Anistreplase | Treprostinil | Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl gro... | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Moderate | 1 | [
[
[
25,
24,
1061
]
],
[
[
25,
24,
885
],
[
885,
40,
1061
]
],
[
[
25,
23,
539
],
[
539,
62,
1061
]
],
[
[
25,
24,
914
],
[
914,
63,
... | [
[
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
]
],
[
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
... | Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol (Compound) resembles Treprostinil (Compound)
Anistreplase may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can ... |
DB01157 | DB09054 | 304 | 384 | [
"DDInter1875",
"DDInter905"
] | Trimetrexate | Idelalisib | A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
304,
24,
384
]
],
[
[
304,
24,
1627
],
[
1627,
62,
384
]
],
[
[
304,
63,
58
],
[
58,
24,
384
]
],
[
[
304,
24,
242
],
[
242,
63,... | [
[
[
"Trimetrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Trimetrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
],
... | Trimetrexate may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Trimetrexate may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Ale... |
DB00738 | DB11057 | 485 | 720 | [
"DDInter1420",
"DDInter1223"
] | Pentamidine | Mineral oil | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
485,
24,
720
]
],
[
[
485,
24,
927
],
[
927,
63,
720
]
],
[
[
485,
24,
1151
],
[
1151,
24,
720
]
],
[
[
485,
25,
1069
],
[
1069,
... | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
... | Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Su... |
DB00906 | DB01233 | 1,567 | 1,311 | [
"DDInter1801",
"DDInter1197"
] | Tiagabine | Metoclopramide | Tiagabine is an anti-convulsive medication. It is also used in the treatment for panic disorder as are a few other anticonvulsants. Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor. | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
1567,
24,
1311
]
],
[
[
1567,
21,
28691
],
[
28691,
60,
1311
]
],
[
[
1567,
63,
1010
],
[
1010,
23,
1311
]
],
[
[
1567,
63,
629
],
[
6... | [
[
[
"Tiagabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Tiagabine",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect) is ... | Tiagabine (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metoclopramide (Compound)
Tiagabine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a minor interaction that can limit clinical effects when taken with Metoc... |
DB00218 | DB01030 | 1,176 | 869 | [
"DDInter1247",
"DDInter1835"
] | Moxifloxacin | Topotecan | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Minor | 0 | [
[
[
1176,
23,
869
]
],
[
[
1176,
23,
613
],
[
613,
24,
869
]
],
[
[
1176,
6,
3199
],
[
3199,
57,
869
]
],
[
[
1176,
21,
29276
],
[
29276,
... | [
[
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Topotecan"
]
],
[
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Irinotecan"
],
[
... | Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Irinotecan and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Moxifloxacin (Compound) binds TOP2A (Gene) and TOP2A (Gene) is downregulated by Topotecan (Compound)
Moxifloxacin... |
DB11057 | DB12161 | 720 | 730 | [
"DDInter1223",
"DDInter512"
] | Mineral oil | Deutetrabenazine | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated . The presence of deuterium in deutetrabenazine increases the half-lives ... | Moderate | 1 | [
[
[
720,
24,
730
]
],
[
[
720,
24,
971
],
[
971,
24,
730
]
],
[
[
720,
63,
688
],
[
688,
24,
730
]
],
[
[
720,
24,
823
],
[
823,
63,... | [
[
[
"Mineral oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Mineral oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]... | Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Salbutamo... |
DB00414 | DB01234 | 590 | 1,220 | [
"DDInter16",
"DDInter513"
] | Acetohexamide | Dexamethasone | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
590,
24,
1220
]
],
[
[
590,
24,
870
],
[
870,
1,
1220
]
],
[
[
590,
24,
175
],
[
175,
40,
1220
]
],
[
[
590,
62,
1103
],
[
1103,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembl... |
DB00673 | DB01115 | 723 | 336 | [
"DDInter112",
"DDInter1291"
] | Aprepitant | Nifedipine | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Moderate | 1 | [
[
[
723,
24,
336
]
],
[
[
723,
63,
1428
],
[
1428,
1,
336
]
],
[
[
723,
63,
1081
],
[
1081,
40,
336
]
],
[
[
723,
24,
409
],
[
409,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isradipine"
],
[
... | Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine (Compound) resembles Nifedipine (Compound)
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Nicardipine and Nicardipine (Compound) resembles Nifedipine (Compound... |
DB08880 | DB10315 | 1,510 | 1,137 | [
"DDInter1771",
"DDInter1127"
] | Teriflunomide | Measles virus vaccine live attenuated | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Major | 2 | [
[
[
1510,
25,
1137
]
],
[
[
1510,
64,
1042
],
[
1042,
24,
1137
]
],
[
[
1510,
25,
119
],
[
119,
64,
1137
]
],
[
[
1510,
64,
273
],
[
273,
... | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetracosactide"
],
... | Teriflunomide may lead to a major life threatening interaction when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Measles virus vaccine live attenuated
Teriflunomide may lead to a major life threatening interaction when taken with Talazopari... |
DB00495 | DB04865 | 139 | 4 | [
"DDInter1961",
"DDInter1335"
] | Zidovudine | Omacetaxine mepesuccinate | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
139,
24,
4
]
],
[
[
139,
18,
8800
],
[
8800,
46,
4
]
],
[
[
139,
18,
2049
],
[
2049,
57,
4
]
],
[
[
139,
7,
9681
],
[
9681,
57,
... | [
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Zidovudine",
"{u} (Compound) downregulates {v} (Gene)",
"RBM34"
],
[
"RBM34",
"{u} (Gene) is upre... | Zidovudine (Compound) downregulates RBM34 (Gene) and RBM34 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Zidovudine (Compound) downregulates MRPS16 (Gene) and MRPS16 (Gene) is downregulated by Omacetaxine mepesuccinate (Compound)
Zidovudine (Compound) upregulates THAP11 (Gene) and THAP11 (Gene) is downr... |
DB01242 | DB05578 | 1,237 | 330 | [
"DDInter410",
"DDInter1566"
] | Clomipramine | Ramucirumab | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stim... | Moderate | 1 | [
[
[
1237,
24,
330
]
],
[
[
1237,
64,
222
],
[
222,
24,
330
]
],
[
[
1237,
63,
121
],
[
121,
24,
330
]
],
[
[
1237,
63,
1317
],
[
1317,
... | [
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramucirumab"
]
],
[
[
"Clomipramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibu... | Clomipramine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine... |
DB00224 | DB00400 | 215 | 353 | [
"DDInter917",
"DDInter843"
] | Indinavir | Griseofulvin | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Moderate | 1 | [
[
[
215,
24,
353
]
],
[
[
215,
6,
8374
],
[
8374,
45,
353
]
],
[
[
215,
21,
28745
],
[
28745,
60,
353
]
],
[
[
215,
63,
168
],
[
168,
... | [
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Griseofulvin"
]
],
[
[
"Indinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Indinavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Griseofulvin (Compound)
Indinavir (Compound) causes Neuropathy peripheral (Side Effect) and Neuropathy peripheral (Side Effect) is caused by Griseofulvin (Compound)
Indinavir may cause a moderate interaction that could exacerbate diseases when taken... |
DB00762 | DB15982 | 613 | 1,339 | [
"DDInter973",
"DDInter193"
] | Irinotecan | Berotralstat | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE. Berotralstat ... | Moderate | 1 | [
[
[
613,
24,
1339
]
],
[
[
613,
63,
1101
],
[
1101,
23,
1339
]
],
[
[
613,
24,
283
],
[
283,
23,
1339
]
],
[
[
613,
24,
1213
],
[
1213,
... | [
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Berotralstat"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedrat... |
DB01359 | DB08816 | 729 | 578 | [
"DDInter1417",
"DDInter1802"
] | Penbutolol | Ticagrelor | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Minor | 0 | [
[
[
729,
23,
578
]
],
[
[
729,
5,
11576
],
[
11576,
44,
578
]
],
[
[
729,
21,
28645
],
[
28645,
60,
578
]
],
[
[
729,
1,
699
],
[
699,
... | [
[
[
"Penbutolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
]
],
[
[
"Penbutolol",
"{u} (Compound) treats {v} (Disease)",
"coronary artery disease"
],
[
"coronary artery disease",
"{u}... | Penbutolol (Compound) treats coronary artery disease (Disease) and coronary artery disease (Disease) is treated by Ticagrelor (Compound)
Penbutolol (Compound) causes Cough (Side Effect) and Cough (Side Effect) is caused by Ticagrelor (Compound)
Penbutolol (Compound) resembles Nadolol (Compound) and Nadolol may cause a ... |
DB11581 | DB11691 | 1,456 | 1,499 | [
"DDInter1926",
"DDInter1258"
] | Venetoclax | Naldemedine | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process,. Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lym... | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opi... | Moderate | 1 | [
[
[
1456,
24,
1499
]
],
[
[
1456,
64,
307
],
[
307,
23,
1499
]
],
[
[
1456,
64,
932
],
[
932,
24,
1499
]
],
[
[
1456,
25,
960
],
[
960,
... | [
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Modafinil"
],
[
"Modafinil"... | Venetoclax may lead to a major life threatening interaction when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Naldemedine
Venetoclax may lead to a major life threatening interaction when taken with Mifepristone and Mifepristone may cause a moderate int... |
DB00363 | DB01362 | 695 | 497 | [
"DDInter419",
"DDInter960"
] | Clozapine | Iohexol | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
695,
25,
497
]
],
[
[
695,
24,
999
],
[
999,
25,
497
]
],
[
[
695,
40,
87
],
[
87,
25,
497
]
],
[
[
695,
25,
1264
],
[
1264,
25,... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylp... | Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may lead to a major life threatening interaction when taken with Iohexol
Clozapine (Compound) resembles Amoxapine (Compound) and Amoxapine may lead to a major life threatening interaction when... |
DB01238 | DB06699 | 673 | 774 | [
"DDInter118",
"DDInter493"
] | Aripiprazole | Degarelix | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Moderate | 1 | [
[
[
673,
24,
774
]
],
[
[
673,
63,
521
],
[
521,
1,
774
]
],
[
[
673,
21,
29232
],
[
29232,
60,
774
]
],
[
[
673,
62,
112
],
[
112,
... | [
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
... | Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Aripiprazole (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Degarelix (Compound)
Aripiprazole may cause a minor interaction t... |
DB05773 | DB08873 | 1,047 | 74 | [
"DDInter1848",
"DDInter221"
] | Trastuzumab emtansine | Boceprevir | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in... | Moderate | 1 | [
[
[
1047,
24,
74
]
],
[
[
1047,
24,
310
],
[
310,
24,
74
]
],
[
[
1047,
63,
309
],
[
309,
24,
74
]
],
[
[
1047,
64,
126
],
[
126,
24... | [
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabaz... | Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB01265 | DB08880 | 1,477 | 1,510 | [
"DDInter1757",
"DDInter1771"
] | Telbivudine | Teriflunomide | Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects. | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Moderate | 1 | [
[
[
1477,
24,
1510
]
],
[
[
1477,
63,
10
],
[
10,
24,
1510
]
],
[
[
1477,
24,
148
],
[
148,
63,
1510
]
],
[
[
1477,
24,
36
],
[
36,
... | [
[
[
"Telbivudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
]
],
[
[
"Telbivudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapsone"
],
[
... | Telbivudine may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Telbivudine may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole and Secnid... |
DB00418 | DB13074 | 536 | 877 | [
"DDInter1650",
"DDInter1110"
] | Secobarbital | Macimorelin | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Moderate | 1 | [
[
[
536,
24,
877
]
],
[
[
536,
24,
112
],
[
112,
23,
877
]
],
[
[
536,
24,
1320
],
[
1320,
24,
877
]
],
[
[
536,
40,
288
],
[
288,
2... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and... |
DB00959 | DB10316 | 1,486 | 334 | [
"DDInter1191",
"DDInter1248"
] | Methylprednisolone | Mumps virus strain B level jeryl lynn live antigen | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Major | 2 | [
[
[
1486,
25,
334
]
],
[
[
1486,
1,
617
],
[
617,
24,
334
]
],
[
[
1486,
64,
1057
],
[
1057,
25,
334
]
],
[
[
1486,
24,
1316
],
[
1316,
... | [
[
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Budesonide"
],
[
"Bu... | Methylprednisolone (Compound) resembles Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Mumps virus strain B level jeryl lynn live antigen
Methylprednisolone may lead to a major life threatening interaction when taken with Etanercept and Etanercept ma... |
DB00526 | DB14443 | 1,555 | 987 | [
"DDInter1355",
"DDInter1931"
] | Oxaliplatin | Vibrio cholerae CVD 103-HgR strain live antigen | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, ... | Moderate | 1 | [
[
[
1555,
24,
987
]
],
[
[
1555,
24,
1480
],
[
1480,
24,
987
]
],
[
[
1555,
63,
141
],
[
141,
24,
987
]
],
[
[
1555,
25,
351
],
[
351,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Oxaliplatin may cause a moderate interaction that could exacerbate diseases wh... |
DB00712 | DB00978 | 1,274 | 739 | [
"DDInter763",
"DDInter1084"
] | Flurbiprofen | Lomefloxacin | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Moderate | 1 | [
[
[
1274,
24,
739
]
],
[
[
1274,
24,
945
],
[
945,
40,
739
]
],
[
[
1274,
63,
1176
],
[
1176,
1,
739
]
],
[
[
1274,
63,
1467
],
[
1467,
... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sparfloxacin"
],
... | Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Lomefloxacin (Compound)
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Lomeflox... |
DB00321 | DB11967 | 21 | 710 | [
"DDInter78",
"DDInter210"
] | Amitriptyline | Binimetinib | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array... | Moderate | 1 | [
[
[
21,
24,
710
]
],
[
[
21,
25,
1593
],
[
1593,
24,
710
]
],
[
[
21,
1,
1237
],
[
1237,
24,
710
]
],
[
[
21,
24,
1557
],
[
1557,
24... | [
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Amitriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Cri... | Amitriptyline may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Amitriptyline (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a moderate interaction that could exa... |
DB01064 | DB06699 | 1,148 | 774 | [
"DDInter987",
"DDInter493"
] | Isoprenaline | Degarelix | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Moderate | 1 | [
[
[
1148,
24,
774
]
],
[
[
1148,
63,
521
],
[
521,
1,
774
]
],
[
[
1148,
21,
28722
],
[
28722,
60,
774
]
],
[
[
1148,
63,
888
],
[
888,
... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
... | Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Isoprenaline (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Degarelix (Compound)
Isoprenaline may cause a moderate interaction that... |
DB00005 | DB00995 | 1,057 | 1,112 | [
"DDInter687",
"DDInter139"
] | Etanercept | Auranofin | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Auranofin is a gold salt that is capable of eliciting pharmacologic actions that suppress inflammation and stimulate cell-mediated immunity. It has subsequently been listed by the World Health Organization as a member of the antirheumatic agent category. Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA. Heme ox... | Moderate | 1 | [
[
[
1057,
24,
1112
]
],
[
[
1057,
25,
36
],
[
36,
63,
1112
]
],
[
[
1057,
25,
134
],
[
134,
24,
1112
]
],
[
[
1057,
24,
1047
],
[
1047,
... | [
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Auranofin"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eribulin"
],
[
"Eribulin",
... | Etanercept may lead to a major life threatening interaction when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Auranofin
Etanercept may lead to a major life threatening interaction when taken with Vinorelbine and Vinorelbine may cause a moderate interac... |
DB00242 | DB08913 | 1,064 | 1,186 | [
"DDInter392",
"DDInter1561"
] | Cladribine | Radium Ra 223 dichloride | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first ap... | Moderate | 1 | [
[
[
1064,
24,
1186
]
],
[
[
1064,
21,
28872
],
[
28872,
60,
1186
]
],
[
[
1064,
25,
37
],
[
37,
24,
1186
]
],
[
[
1064,
25,
1583
],
[
1583... | [
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Cladribine",
"{u} (Compound) causes {v} (Side Effect)",
"Extravasation"
],
[
"Extravasation",
"{u}... | Cladribine (Compound) causes Extravasation (Side Effect) and Extravasation (Side Effect) is caused by Radium Ra 223 dichloride (Compound)
Cladribine may lead to a major life threatening interaction when taken with Lomustine and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Ra... |
DB00889 | DB01168 | 1,133 | 1,053 | [
"DDInter840",
"DDInter1526"
] | Granisetron | Procarbazine | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Major | 2 | [
[
[
1133,
25,
1053
]
],
[
[
1133,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
1133,
25,
246
],
[
246,
23,
1053
]
],
[
[
1133,
24,
739
],
[
739... | [
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Granisetron",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Co... | Granisetron (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Granisetron may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Procarbazine
Grani... |
DB00317 | DB00559 | 883 | 152 | [
"DDInter810",
"DDInter223"
] | Gefitinib | Bosentan | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Moderate | 1 | [
[
[
883,
24,
152
]
],
[
[
883,
6,
6017
],
[
6017,
45,
152
]
],
[
[
883,
21,
29402
],
[
29402,
60,
152
]
],
[
[
883,
63,
1101
],
[
1101,
... | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosentan"
]
],
[
[
"Gefitinib",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Gefitinib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Bosentan (Compound)
Gefitinib (Compound) causes Hepatobiliary disease (Side Effect) and Hepatobiliary disease (Side Effect) is caused by Bosentan (Compound)
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Be... |
DB01019 | DB09268 | 427 | 1,662 | [
"DDInter199",
"DDInter1464"
] | Bethanechol | Picosulfuric acid | Bethanechol is a synthetic ester that was initially synthesized in 1935.[A232905,L32539] As a cholinergic agent, bethanechol is similar in structure and pharmacological function to acetylcholine and is used in specific cases when stimulation of the parasympathetic nervous system is necessary.[A232905,L32539] For exampl... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
427,
24,
1662
]
],
[
[
427,
63,
1528
],
[
1528,
24,
1662
]
],
[
[
427,
25,
593
],
[
593,
24,
1662
]
],
[
[
427,
63,
1528
],
[
1528,
... | [
[
[
"Bethanechol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Bethanechol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
... | Bethanechol may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine and Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Bethanechol may lead to a major life threatening interaction when taken with Bupropion and Bupropi... |
DB00867 | DB09038 | 1,052 | 1,450 | [
"DDInter1606",
"DDInter636"
] | Ritodrine | Empagliflozin | Adrenergic beta-agonist used to control premature labor. | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
1052,
24,
1450
]
],
[
[
1052,
63,
485
],
[
485,
24,
1450
]
],
[
[
1052,
24,
659
],
[
659,
63,
1450
]
],
[
[
1052,
23,
1486
],
[
1486,
... | [
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
... | Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vil... |
DB00813 | DB11186 | 704 | 1,609 | [
"DDInter722",
"DDInter1427"
] | Fentanyl | Pentoxyverine | Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and... | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma... | Moderate | 1 | [
[
[
704,
24,
1609
]
],
[
[
704,
24,
104
],
[
104,
24,
1609
]
],
[
[
704,
63,
999
],
[
999,
24,
1609
]
],
[
[
704,
1,
1322
],
[
1322,
... | [
[
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
... | Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine a... |
DB01036 | DB01156 | 211 | 593 | [
"DDInter1832",
"DDInter252"
] | Tolterodine | Bupropion | Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors. | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Minor | 0 | [
[
[
211,
23,
593
]
],
[
[
211,
6,
8374
],
[
8374,
45,
593
]
],
[
[
211,
21,
28757
],
[
28757,
60,
593
]
],
[
[
211,
63,
752
],
[
752,
... | [
[
[
"Tolterodine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bupropion"
]
],
[
[
"Tolterodine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Tolterodine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bupropion (Compound)
Tolterodine (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Bupropion (Compound)
Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cim... |
DB00486 | DB01175 | 1,614 | 318 | [
"DDInter1253",
"DDInter672"
] | Nabilone | Escitalopram | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Moderate | 1 | [
[
[
1614,
24,
318
]
],
[
[
1614,
63,
1230
],
[
1230,
1,
318
]
],
[
[
1614,
21,
28641
],
[
28641,
60,
318
]
],
[
[
1614,
63,
999
],
[
999,
... | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
[
... | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Nabilone (Compound) causes Hot flush (Side Effect) and Hot flush (Side Effect) is caused by Escitalopram (Compound)
Nabilone may cause a moderate interaction th... |
DB00193 | DB09330 | 534 | 985 | [
"DDInter1841",
"DDInter1352"
] | Tramadol | Osimertinib | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
534,
25,
985
]
],
[
[
534,
23,
112
],
[
112,
23,
985
]
],
[
[
534,
25,
608
],
[
608,
23,
985
]
],
[
[
534,
24,
480
],
[
480,
24,... | [
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Tramadol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazol... | Tramadol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Tramadol may lead to a major life threatening interaction when taken with Lidocaine and Lidocaine may cause a m... |
DB00957 | DB11986 | 873 | 484 | [
"DDInter1314",
"DDInter648"
] | Norgestimate | Entrectinib | Norgestimate was first described in the literature in 1977. It was developed by Ortho Pharmaceutical Corporation as part of an effort to develop new hormonal contraceptives with reduced adverse effects. It is commonly formulated with [ethinylestradiol] as a combined oral contraceptive that can also be used to treat mod... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
873,
24,
484
]
],
[
[
873,
40,
1197
],
[
1197,
24,
484
]
],
[
[
873,
25,
927
],
[
927,
24,
484
]
],
[
[
873,
24,
1362
],
[
1362,
... | [
[
[
"Norgestimate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Norgestimate",
"{u} (Compound) resembles {v} (Compound)",
"Norethisterone"
],
[
"Norethisterone",
"{u} may ca... | Norgestimate (Compound) resembles Norethisterone (Compound) and Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Norgestimate may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could... |
DB00574 | DB00757 | 121 | 1,166 | [
"DDInter717",
"DDInter581"
] | Fenfluramine | Dolasetron | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Major | 2 | [
[
[
121,
25,
1166
]
],
[
[
121,
63,
828
],
[
828,
24,
1166
]
],
[
[
121,
23,
479
],
[
479,
63,
1166
]
],
[
[
121,
24,
688
],
[
688,
... | [
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
],
[
"Oxycodo... | Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Dolasetron
Fenfluramine may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepez... |
DB00745 | DB06603 | 307 | 39 | [
"DDInter1236",
"DDInter1387"
] | Modafinil | Panobinostat | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron ac... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Moderate | 1 | [
[
[
307,
24,
39
]
],
[
[
307,
1,
282
],
[
282,
63,
39
]
],
[
[
307,
24,
455
],
[
455,
24,
39
]
],
[
[
307,
24,
578
],
[
578,
63,
... | [
[
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Modafinil",
"{u} (Compound) resembles {v} (Compound)",
"Nepafenac"
],
[
"Nepafenac",
"{u} may cause a moderate ... | Modafinil (Compound) resembles Nepafenac (Compound) and Nepafenac may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could e... |
DB00476 | DB09291 | 109 | 741 | [
"DDInter608",
"DDInter1615"
] | Duloxetine | Rolapitant | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Moderate | 1 | [
[
[
109,
24,
741
]
],
[
[
109,
25,
506
],
[
506,
24,
741
]
],
[
[
109,
40,
758
],
[
758,
24,
741
]
],
[
[
109,
24,
401
],
[
401,
24,... | [
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
]
],
[
[
"Duloxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextromethorphan"
],
[
"Dext... | Duloxetine may lead to a major life threatening interaction when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Duloxetine (Compound) resembles Fluoxetine (Compound) and Fluoxetine may cause a moderate interaction that could ex... |
DB00013 | DB00682 | 1,255 | 126 | [
"DDInter1905",
"DDInter1951"
] | Urokinase | Warfarin | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Major | 2 | [
[
[
1255,
25,
126
]
],
[
[
1255,
23,
944
],
[
944,
62,
126
]
],
[
[
1255,
24,
477
],
[
477,
62,
126
]
],
[
[
1255,
24,
557
],
[
557,
... | [
[
[
"Urokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
]
],
[
[
"Urokinase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
... | Urokinase may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Warfarin
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may c... |
DB00679 | DB06203 | 684 | 1,002 | [
"DDInter1796",
"DDInter51"
] | Thioridazine | Alogliptin | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Moderate | 1 | [
[
[
684,
24,
1002
]
],
[
[
684,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
684,
6,
12523
],
[
12523,
45,
1002
]
],
[
[
684,
21,
29081
],
[
2908... | [
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
... | Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Thioridazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Alogliptin (Compound)
Thioridazine (Compound) causes Angioedema (Side Effect) and ... |
DB00916 | DB06772 | 112 | 310 | [
"DDInter1202",
"DDInter259"
] | Metronidazole | Cabazitaxel | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Moderate | 1 | [
[
[
112,
24,
310
]
],
[
[
112,
24,
973
],
[
973,
24,
310
]
],
[
[
112,
6,
3486
],
[
3486,
45,
310
]
],
[
[
112,
21,
28692
],
[
28692,
... | [
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
... | Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Metronidazole (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Cabazitaxel (Compound)
Metronidaz... |
DB01579 | DB09045 | 341 | 52 | [
"DDInter1439",
"DDInter607"
] | Phendimetrazine | Dulaglutide | Phendimetrazine is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances and in the US since 1970. | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
341,
24,
52
]
],
[
[
341,
63,
170
],
[
170,
23,
52
]
],
[
[
341,
64,
73
],
[
73,
24,
52
]
],
[
[
341,
63,
1152
],
[
1152,
24,
... | [
[
[
"Phendimetrazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Phendimetrazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
... | Phendimetrazine may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Phendimetrazine may lead to a major life threatening interaction when taken with Phentermine and Phentermi... |
DB00414 | DB01232 | 590 | 1,327 | [
"DDInter16",
"DDInter1640"
] | Acetohexamide | Saquinavir | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Moderate | 1 | [
[
[
590,
24,
1327
]
],
[
[
590,
63,
798
],
[
798,
40,
1327
]
],
[
[
590,
24,
915
],
[
915,
40,
1327
]
],
[
[
590,
24,
222
],
[
222,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nelfinavir"
],
... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir (Compound) resembles Saquinavir (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir (Compound) resembles Saquinavir (Comp... |
DB00792 | DB00835 | 832 | 100 | [
"DDInter1878",
"DDInter245"
] | Tripelennamine | Brompheniramine | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
832,
24,
100
]
],
[
[
832,
40,
508
],
[
508,
24,
100
]
],
[
[
832,
1,
11786
],
[
11786,
40,
100
]
],
[
[
832,
63,
128
],
[
128,
... | [
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Tripelennamine",
"{u} (Compound) resembles {v} (Compound)",
"Promazine"
],
[
"Promazine",
"{u} may caus... | Tripelennamine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Tripelennamine (Compound) resembles Captodiame (Compound) and Captodiame (Compound) resembles Brompheniramine (Compound)
Tripelennamine may cause a moder... |
DB01128 | DB01238 | 918 | 673 | [
"DDInter204",
"DDInter118"
] | Bicalutamide | Aripiprazole | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Moderate | 1 | [
[
[
918,
24,
673
]
],
[
[
918,
63,
827
],
[
827,
40,
673
]
],
[
[
918,
63,
1630
],
[
1630,
1,
673
]
],
[
[
918,
6,
12523
],
[
12523,
... | [
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trazodone"
],
... | Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Aripiprazole (Compound)
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Aripiprazole (... |
DB11793 | DB11979 | 738 | 1,320 | [
"DDInter1297",
"DDInter625"
] | Niraparib | Elagolix | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
738,
24,
1320
]
],
[
[
738,
63,
168
],
[
168,
23,
1320
]
],
[
[
738,
24,
1612
],
[
1612,
23,
1320
]
],
[
[
738,
63,
129
],
[
129,
... | [
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir... |
DB00635 | DB12130 | 1,573 | 1,017 | [
"DDInter1515",
"DDInter1094"
] | Prednisone | Lorlatinib | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
1573,
24,
1017
]
],
[
[
1573,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
1573,
63,
590
],
[
590,
24,
1017
]
],
[
[
1573,
1,
175
],
[
175,
... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Aceto... |
DB09074 | DB11601 | 1,362 | 1,270 | [
"DDInter1327",
"DDInter1889"
] | Olaparib | Tuberculin purified protein derivative | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
1362,
24,
1270
]
],
[
[
1362,
63,
350
],
[
350,
24,
1270
]
],
[
[
1362,
64,
1064
],
[
1064,
24,
1270
]
],
[
[
1362,
24,
119
],
[
119,
... | [
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Car... | Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Olaparib may lead to a major life threatening interaction when taken with Cladribine... |
DB00581 | DB06616 | 355 | 594 | [
"DDInter1018",
"DDInter224"
] | Lactulose | Bosutinib | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Moderate | 1 | [
[
[
355,
24,
594
]
],
[
[
355,
21,
28709
],
[
28709,
60,
594
]
],
[
[
355,
23,
460
],
[
460,
63,
594
]
],
[
[
355,
24,
786
],
[
786,
... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Lactulose",
"{u} (Compound) causes {v} (Side Effect)",
"Decreased appetite"
],
[
"Decreased appetite",
"{u} (Side ... | Lactulose (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Bosutinib (Compound)
Lactulose may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate and Magnesium carbonate may cause a moderate interaction that could exacerbate d... |
DB08987 | DB14740 | 799 | 771 | [
"DDInter697",
"DDInter881"
] | Etidocaine | Hyaluronidase | Etidocaine is marketed under the name Duranest. It is an injectable local anesthetic during surgery, labor, and delivery. Etidocaine has a long duration of activity, but has the main disadvantage of increased bleeding during oral surgery. | Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents. The action of hyaluronidase was first described in 1936, and named in 1939. Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permea... | Minor | 0 | [
[
[
799,
23,
771
]
],
[
[
799,
40,
608
],
[
608,
23,
771
]
],
[
[
799,
6,
6115
],
[
6115,
45,
815
],
[
815,
23,
771
]
],
[
[
799,
40... | [
[
[
"Etidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
]
],
[
[
"Etidocaine",
"{u} (Compound) resembles {v} (Compound)",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor in... | Etidocaine (Compound) resembles Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Etidocaine (Compound) binds SCN2A (Gene) and SCN2A (Gene) is bound by Mepivacaine (Compound) and Mepivacaine may cause a minor interaction that can limit clinica... |
DB04868 | DB11796 | 478 | 1,612 | [
"DDInter1293",
"DDInter786"
] | Nilotinib | Fostemsavir | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in the... | Major | 2 | [
[
[
478,
25,
1612
]
],
[
[
478,
63,
1051
],
[
1051,
23,
1612
]
],
[
[
478,
24,
98
],
[
98,
23,
1612
]
],
[
[
478,
24,
1476
],
[
1476,
... | [
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostemsavir"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
],
[
"Amin... | Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem a... |
DB00348 | DB01142 | 254 | 1,264 | [
"DDInter1300",
"DDInter593"
] | Nitisinone | Doxepin | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
254,
24,
1264
]
],
[
[
254,
24,
1335
],
[
1335,
24,
1264
]
],
[
[
254,
21,
28809
],
[
28809,
60,
1264
]
],
[
[
254,
24,
463
],
[
463,
... | [
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
],
[
... | Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Nitisinone (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Doxepin (Compou... |
DB00938 | DB14509 | 455 | 1,399 | [
"DDInter1635",
"DDInter1081"
] | Salmeterol | Lithium carbonate | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
455,
24,
1399
]
],
[
[
455,
63,
874
],
[
874,
23,
1399
]
],
[
[
455,
24,
1385
],
[
1385,
24,
1399
]
],
[
[
455,
63,
1010
],
[
1010,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide an... |
DB00370 | DB11057 | 1,251 | 720 | [
"DDInter1230",
"DDInter1223"
] | Mirtazapine | Mineral oil | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
1251,
24,
720
]
],
[
[
1251,
24,
927
],
[
927,
63,
720
]
],
[
[
1251,
24,
1151
],
[
1151,
24,
720
]
],
[
[
1251,
25,
1069
],
[
1069,
... | [
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
... | Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Su... |
DB00169 | DB00312 | 386 | 1,023 | [
"DDInter367",
"DDInter1423"
] | Cholecalciferol | Pentobarbital | Vitamin D, in general, is a secosteroid generated in the skin when 7-dehydrocholesterol located there interacts with ultraviolet irradiation - like that commonly found in sunlight. Both the endogenous form of vitamin D (that results from 7-dehydrocholesterol transformation), vitamin D3 (cholecalciferol), and the plant-... | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Dr... | Moderate | 1 | [
[
[
386,
24,
1023
]
],
[
[
386,
24,
288
],
[
288,
40,
1023
]
],
[
[
386,
6,
10215
],
[
10215,
45,
1023
]
],
[
[
386,
23,
752
],
[
752,
... | [
[
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentobarbital"
]
],
[
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Butalbital"
... | Cholecalciferol may cause a moderate interaction that could exacerbate diseases when taken with Butalbital and Butalbital (Compound) resembles Pentobarbital (Compound)
Cholecalciferol (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Pentobarbital (Compound)
Cholecalciferol may cause a minor interaction th... |
DB00877 | DB08899 | 629 | 129 | [
"DDInter1678",
"DDInter649"
] | Sirolimus | Enzalutamide | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Major | 2 | [
[
[
629,
25,
129
]
],
[
[
629,
24,
918
],
[
918,
1,
129
]
],
[
[
629,
6,
8374
],
[
8374,
45,
129
]
],
[
[
629,
21,
28703
],
[
28703,
... | [
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
[
"Bicaluta... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Sirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Sirolimus (Compound) causes Pruritus (Side Effect) and Pruri... |
DB01229 | DB14568 | 973 | 982 | [
"DDInter1377",
"DDInter1000"
] | Paclitaxel | Ivosidenib | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Moderate | 1 | [
[
[
973,
24,
982
]
],
[
[
973,
63,
112
],
[
112,
23,
982
]
],
[
[
973,
25,
976
],
[
976,
24,
982
]
],
[
[
973,
63,
700
],
[
700,
24,... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Paclitaxel may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may ... |
DB00994 | DB09156 | 361 | 777 | [
"DDInter1277",
"DDInter964"
] | Neomycin | Iopromide | Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of _Streptomyces fradiae_. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as [framycetin], is the most active component of the complex and neomycin C is the isomer o... | Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. It functions as a contrast agent by opacifying blood vessels in the flow path of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs. Although iopromide can... | Major | 2 | [
[
[
361,
25,
777
]
],
[
[
361,
64,
1028
],
[
1028,
24,
777
]
],
[
[
361,
23,
699
],
[
699,
24,
777
]
],
[
[
361,
24,
242
],
[
242,
6... | [
[
[
"Neomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iopromide"
]
],
[
[
"Neomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Torasemide"
],
[
"Torasemide",
"{u} may ca... | Neomycin may lead to a major life threatening interaction when taken with Torasemide and Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Iopromide
Neomycin may cause a minor interaction that can limit clinical effects when taken with Nadolol and Nadolol may cause a moderate in... |
DB00414 | DB01097 | 590 | 1,377 | [
"DDInter16",
"DDInter1033"
] | Acetohexamide | Leflunomide | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Moderate | 1 | [
[
[
590,
24,
1377
]
],
[
[
590,
24,
1144
],
[
1144,
24,
1377
]
],
[
[
590,
24,
852
],
[
852,
63,
1377
]
],
[
[
590,
63,
1028
],
[
1028,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Activated ch... |
DB00813 | DB01168 | 704 | 1,053 | [
"DDInter722",
"DDInter1526"
] | Fentanyl | Procarbazine | Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and... | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Major | 2 | [
[
[
704,
25,
1053
]
],
[
[
704,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
704,
24,
100
],
[
100,
24,
1053
]
],
[
[
704,
24,
830
],
[
830,
... | [
[
[
"Fentanyl",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Fentanyl",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound... | Fentanyl (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with P... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.